Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Oxazepam
Drug ID BADD_D01636
Description Oxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. Oxazepam, like related 3-hydroxybenzodiazepine [lorazepam], is considered less susceptible to pharmacokinetic variability based on patient-specific factors (e.g. age, liver disease) - this feature is advantageous as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism.[A203516] It is an active metabolite of both [diazepam] and [temazepam][A39486] and undergoes very little biotransformation following absorption, making it unlikely to participate in pharmacokinetic interactions.[L13895]
Indications and Usage Oxazepam is indicated for the management of anxiety disorders and for the short-term relief of symptoms of anxiety.[L13895] It may also be used in the management of alcohol withdrawal symptoms.[L13895]
Marketing Status approved
ATC Code N05BA04
DrugBank ID DB00842
KEGG ID D00464
MeSH ID D010076
PubChem ID 4616
TTD Drug ID D09LDR
NDC Product Code 64330-015; 12828-0024; 43353-965; 52817-292; 71610-639; 62584-814; 48087-0087; 72166-009; 43353-980; 52817-291; 62584-813; 0228-2073; 62584-812; 0228-2069; 0228-2067; 52817-290
UNII 6GOW6DWN2A
Synonyms Oxazepam | Serax | Tazepam | Adumbran
Chemical Information
Molecular Formula C15H11ClN2O2
CAS Registry Number 604-75-1
SMILES C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypersomnia19.02.05.001; 17.15.01.001--
Hypertension24.08.02.0010.004559%
Hyperthermia12.05.01.002; 08.05.01.0010.001520%Not Available
Hypoaesthesia23.03.03.081; 17.02.06.0230.001520%Not Available
Hypokalaemia14.05.03.0020.003040%
Hypokinesia17.01.02.0090.001520%Not Available
Hyponatraemia14.05.04.0020.004559%
Hypotension24.06.03.0020.012158%
Hypothermia12.05.03.001; 08.05.01.0030.003040%
Incontinence20.02.02.004; 17.05.01.006; 07.01.06.011--Not Available
Initial insomnia19.02.01.005; 17.15.03.0050.001520%Not Available
Insomnia19.02.01.002; 17.15.03.0020.001520%
Intentional self-injury12.01.08.036; 19.12.01.0020.004559%Not Available
Jaundice09.01.01.004; 23.03.03.030; 01.06.04.004--Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.008--
Leukopenia01.02.02.001--Not Available
Loss of consciousness17.02.04.0040.001520%Not Available
Malaise08.01.01.0030.003800%
Mass08.03.05.003--Not Available
Memory impairment19.20.01.003; 17.03.02.0030.003040%
Menstruation irregular21.01.01.005; 05.05.01.008--
Miosis06.05.03.003; 17.02.11.0020.003040%Not Available
Muscle rigidity17.05.02.005; 15.05.04.0010.003800%Not Available
Muscle spasms15.05.03.0040.003040%
Muscular weakness17.05.03.005; 15.05.06.001--
Myalgia15.05.02.0010.001520%
Mydriasis17.02.11.003; 06.05.03.0040.005319%Not Available
Myocardial infarction24.04.04.009; 02.02.02.0070.001520%
Nausea07.01.07.001--
Neuroleptic malignant syndrome12.03.01.003; 08.05.01.005; 17.05.02.003; 15.05.04.0150.001520%Not Available
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages